TLDR The enzyme myo-inositol oxygenase is not linked to the cause of polycystic ovarian syndrome.
The study compared serum myo-inositol oxygenase (MIOX) levels in 60 newly diagnosed PCOS patients with 60 healthy controls and found no significant difference, indicating that MIOX does not contribute to the etiology of PCOS. Median MIOX levels were 19.4 in the control group and 16.4 in the PCOS group, with a p-value of 0.7428. The only noted difference between the groups was a higher lymphocyte count in the PCOS group. The study suggests that myo-inositol deficiency in PCOS is not due to altered MIOX levels and acknowledges the limitation of not measuring urinary MIOX and inositol levels, recommending further research into alternative myo-inositol clearance mechanisms.
369 citations,
June 2013 in “Biochimie” Myo-inositol supplements may improve insulin sensitivity and help with conditions like PCOS and gestational diabetes, but more research is needed.
4809 citations,
January 2004 in “Fertility and Sterility” The 2003 consensus updated PCOS diagnosis criteria and highlighted increased risks of diabetes and heart disease for those affected.
369 citations,
June 2013 in “Biochimie” Myo-inositol supplements may improve insulin sensitivity and help with conditions like PCOS and gestational diabetes, but more research is needed.
October 2023 in “Frontiers in endocrinology” Effective PCOS treatments require targeting specific signaling pathways.
November 2023 in “Curēus” Melatonin may help manage PCOS by improving insulin sensitivity, hormone balance, and mood.
1 citations,
November 2011 in “British journal of pharmacology” Enzymes are classified into six types and are essential for many biological processes, with only a few targeted by drugs.
13 citations,
October 2010 in “Pharmacogenomics” Researchers found that most genes affecting drug responses are not fully covered by commercial SNP chips, suggesting the need for more comprehensive tools to optimize drug selection based on genetics.
